Fact Sheet/Brochure

This guidance document provides information regarding issuance of updated DEA registration certificates to reflect Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).

This letter announces details on Congress's elimination of the X-waiver (DATA-Waiver) to increase buprenorphine accessibility in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).

This handout provides definitions for the most common terms used in discussing why health equity matters in prevention.

This handout is designed to assist both newly formed and seasoned prevention coalitions to determine the who, what, and how to reduce health disparities as they implement substance misuse prevention programs.

This fact sheet provides guidance for patients starting buprenorphine outside of hospitals or clinics.

This NIDA fact sheet provides information on the relationship between drug use and viral infections.

This fact sheet provides healthcare providers and people who use drugs with an overview of fentanyl and fentanyl test strips to prevent overdose. Other harm reduction strategies are also provided.

This fact sheet provides an overview of the Medication First (or low-barrier maintenance pharmacotherapy) approach to the treatment of opioid use disorders.

This sheet from the CDC provides techniques for talking with patients and their families about substance use disorder.

This sheet provides ideas to tackle stigma and develop an Action Plan to reduce stigma in organizations.